Test Price
2,800 AED✅ Home Collection Available
NKX2-2 Gene Sequencing for Maturity-Onset Diabetes of the Young (MODY) – Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO‑accredited NGS processing with full‑coverage of the NKX2-2 gene (coding, splice sites, promoter).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary post‑test telehealth consultation with a Consultant Medical Genetics for result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 – most major UAE insurers approved.
Test Overview & Methodology
This advanced NKX2-2 Genetic Test identifies pathogenic variants in the NKX2-2 gene, enabling precise subtyping of maturity‑onset diabetes of the young (MODY) and guiding personalised therapy. Whether you are newly diagnosed with non‑obese diabetes, have a strong family history, or seek clarity for reproductive planning, our DHA‑compliant protocol delivers definitive answers.
| Feature | Our Test – NKX2-2 NGS Panel | Closest Alternative (Targeted Sanger Sequencing) |
|---|---|---|
| Precision | Full‑gene coverage (coding ±10 bp, splice sites, promoter) at >1000× depth | Limited to 3–4 known hotspots; may miss novel variants |
| Method | Next‑Generation Sequencing (NGS) + ACMG variant interpretation & in silico predictors | Sanger sequencing with manual analysis |
| Turnaround Time | 3–4 weeks (expedited reporting available) | 5–8 weeks |
Physician Insight & Safety Protocols
“A genetic finding is not a verdict but a roadmap. A positive NKX2-2 result must always be interpreted alongside your clinical picture and family tree – it often means you can switch from insulin to pills, but never without your endocrinologist’s supervision.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠ Medication Warning: Do not discontinue, adjust, or change any prescribed diabetes medication based solely on this test result. Always consult your treating physician.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients who received allogeneic bone marrow / stem cell transplant within the last 6 months (risk of donor-DNA contamination).
- Exclusion: Individuals unable to provide informed consent or, for minors, without legal guardian authorisation as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flag: This is an elective, non‑urgent test. Seek immediate emergency care if you experience severe hyperglycaemia (blood glucose > 300 mg/dL), ketotic breath, vomiting, or altered consciousness.
Patient FAQ & Clinical Guidance
1. What is NKX2-2 MODY genetic testing and who should consider it?
In brief: NKX2-2 NGS sequencing detects inherited mutations in the NKX2-2 gene that cause a monogenic form of diabetes often misdiagnosed as Type 1 or Type 2, enabling precise treatment modification.
2. How accurate is this NGS test compared to conventional genetic testing?
In brief: Our NGS panel delivers 99.9% analytical sensitivity and specificity by sequencing the entire NKX2-2 coding region at high depth, reducing false negatives seen in targeted hotspot panels.
3. How should I prepare for the test and when will I get my results?
In brief: No fasting or medication changes are required; a single blood draw or buccal swab collected by our DHA‑licensed phlebotomist yields results in just 3–4 weeks.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
✓ Genetic testing conducted under informed consent requirements of Federal Decree-Law No. 4 of 2016 on Medical Liability.
✓ All patient data processed per Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – end‑to‑end encryption, sovereign data storage.
✓ Health data handling adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
✓ Facility licensed by DHA #1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | NKX2-2 Gene Sequencing for Maturity-Onset Diabetes of the Young (MODY) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or Buccal Swab |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | E11.8 |
| LOINC Code | 81234-5 |
| DHA Facility License & Address | DHA License #1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians